THERAPY DOSSIER · th-ce6848e95a6e

alpha-conotoxin RgIA

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25008370 ↗2014Reported benefit

alpha-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement.

RatOtherSprague-DawleyMalen = 12 rats per group for behaviour (2 experimental sets); 6 ra…Intramuscular, into the ipsilateral paw muscle2 nmol or 10 nmol in 100 microlitres sterile salineFirst dose 60 min after surgery, after recovery from anaesthesia

Model: Chronic constriction injury (CCI) of the right sciatic nerve, four loose chromic gut ligatures at 1 mm spacing

Fourteen days of RgIA prevented hypersensitivity: paw pressure threshold rose to 61.7 plus or minus 0.6 g (2 nmol) and 65.0 plus or minus 0.9 g (10 nmol) versus 39.2 plus or minus 1.3 g for CCI plus vehicle, with von Frey thresholds also preserved and postural imbalance relieved by 62% and 74% resp…

Extraction: extract · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.

Loading the evidence…